截至2025年4月24日 09:50，创新药企ETF(560900)上涨1.80%，盘中成交额不断走阔。跟踪指数中证创 新药产业指数(931152)强势上涨1.60%，成分股凯莱英(002821)上涨10.01%，迈威生物(688062)上涨 7.23%，荣昌生物(688331)上涨6.57%，泽璟制药(688266)，浙江医药(600216)等个股跟涨。 银河证券分析认为，创新药企正处于关键转型期，长春高新2024年研发投入达26.90亿元，同比增长 11.20%，占营收比重近20%。公司积极推进生长激素产品的适应症拓展和海外布局，长效生长激素实现 自产自用，同时促卵泡激素水剂等新产品陆续上市。 此外，摩根旗下相关ETF还有布局港股科技龙头的摩根恒生科技ETF(QDII)(513890)，捕捉绿色中国投资 机遇的摩根中证碳中和60ETF(560960)，布局中国核心资产的摩根MSCI中国A股ETF(515770)，以及布 局硬科技领域的科创信息技术ETF摩根(588770)。 伴随AI驱动新一轮科技浪潮的兴起，摩根资产管理整合旗下"全球视野投科技"产品线，从主动管理到被 动投资产品，助力投资者从全球视野布局 ...

Group 1: Innovation Drug Sector Performance - The Innovation Drug ETF (560900) increased by 1.03% with a turnover of 7.72% and a transaction volume of 2.9414 million yuan as of April 22, 2025 [1] - The CSI Innovation Drug Industry Index (931152) rose by 0.94%, with notable increases in constituent stocks such as Baili Tianheng (688506) up 6.72%, Zhongsheng Pharmaceutical (002317) up 6.41%, and Dongcheng Pharmaceutical (002675) up 4.60% [1] - The Innovation Drug ETF (560900) saw a significant growth of 1.4674 million yuan in scale this month, ranking it 1st among comparable funds [1] Group 2: Market Opportunities and Trends - The innovation drug sector is experiencing new development opportunities, particularly due to changes in trade relations that may lead to increased tariffs on imported drugs from the U.S., benefiting domestic innovative drug products [1] - There is substantial potential for domestic substitution in the fields of blood products, high-end medical devices, and innovative drugs, as China's innovative drug research and development accelerates [1] - The market has shown a continuous rebound in the innovation drug sector, with companies exporting to non-standard markets performing particularly well [1] Group 3: Morgan Asset Management Products - Morgan Asset Management has a range of ETFs including the Morgan Hang Seng Technology ETF (QDII) (513890) and the Morgan China Core Assets ETF (515770), aimed at capturing investment opportunities in technology and carbon neutrality [2] - The firm integrates its "Global Vision Investment Technology" product line to assist investors in seizing investment opportunities in quality technology companies globally [2] - Active management funds focus on emerging industry trends, artificial intelligence, and sectors like new energy vehicles and humanoid robots [2]